For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $5.57 in the prior trading day, Cytek BioSciences Inc (NASDAQ: CTKB) closed at $5.27, down -5.39%. In other words, the price has decreased by -$5.39 from its previous closing price. On the day, 0.68 million shares were traded. CTKB stock price reached its highest trading level at $5.59 during the session, while it also had its lowest trading level at $5.255.
Ratios:
Our goal is to gain a better understanding of CTKB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.48 and its Current Ratio is at 5.17. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 09, 2025, TD Cowen Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $4.
Goldman Downgraded its Buy to Sell on January 31, 2025, whereas the target price for the stock was revised from $7 to $4.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 02 ’25 when McCombe William D. bought 35,000 shares for $2.78 per share. The transaction valued at 97,300 led to the insider holds 55,746 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 673847680 and an Enterprise Value of 436939648. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.42 while its Price-to-Book (P/B) ratio in mrq is 1.78. Its current Enterprise Value per Revenue stands at 2.22 whereas that against EBITDA is -16.263.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.30, which has changed by -0.08027923 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $6.18, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 0.71%, while the 200-Day Moving Average is calculated to be 30.64%.
Shares Statistics:
The stock has traded on average 1.28M shares per day over the past 3-months and 916810 shares per day over the last 10 days, according to various share statistics. A total of 127.86M shares are outstanding, with a floating share count of 115.96M. Insiders hold about 9.31% of the company’s shares, while institutions hold 62.73% stake in the company. Shares short for CTKB as of 1767139200 were 6532567 with a Short Ratio of 5.12, compared to 1764288000 on 6927855. Therefore, it implies a Short% of Shares Outstanding of 6532567 and a Short% of Float of 6.6300004999999995.
Earnings Estimates
The company has 2.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.04 and -$0.01 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is -$0.01, with 2.0 analysts recommending between -$0.01 and -$0.02.
Revenue Estimates
1 analysts predict $58.8M in revenue. The current quarter. It ranges from a high estimate of $58.8M to a low estimate of $58.8M. The current estimate, Cytek BioSciences Inc’s year-ago sales were $57.48MFor the next quarter, 1 analysts are estimating revenue of $43.65M. There is a high estimate of $44.9M for the next quarter, whereas the lowest estimate is $42.62M.
A total of 4 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $198M, while the lowest revenue estimate was $196.2M, resulting in an average revenue estimate of $196.87M. In the same quarter a year ago, actual revenue was $200.45MBased on 5 analysts’ estimates, the company’s revenue will be $207.42M in the next fiscal year. The high estimate is $210M and the low estimate is $205M.
